CA2267421A1 - Administration orale d'anticorps a base de jaune d'oeuf de poule pour le traitement de maladies - Google Patents

Administration orale d'anticorps a base de jaune d'oeuf de poule pour le traitement de maladies Download PDF

Info

Publication number
CA2267421A1
CA2267421A1 CA002267421A CA2267421A CA2267421A1 CA 2267421 A1 CA2267421 A1 CA 2267421A1 CA 002267421 A CA002267421 A CA 002267421A CA 2267421 A CA2267421 A CA 2267421A CA 2267421 A1 CA2267421 A1 CA 2267421A1
Authority
CA
Canada
Prior art keywords
egg
antibodies
mediator
antibody
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002267421A
Other languages
English (en)
Inventor
Marilyn A. Coleman
Mitchell V. Kaminski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ovimmune Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2267421A1 publication Critical patent/CA2267421A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/02—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Globalement, l'invention concerne l'utilisation de préparations d'anticorps à base d'oeuf pour le traitement de maladies touchant l'organisme entier, chez l'homme et chez d'autres mammifères. On obtient d'abord les anticorps IgY à partir d'oeufs d'une pondeuse domestique immunisée activement contre un ou plusieurs des organismes pathogènes considérés, par injection d'un immunogène contenant des déterminants immunogènes propres au déclenchement des anticorps. On administre ensuite oralement ces anticorps à un mammifère souffrant d'une maladie infectieuse touchant l'organisme, laquelle est provoquée ou accentuée par le ou lesdits organismes pathogènes. Il en résulte une immunisation passive pour les sujets à système immunitaire défaillant ou naïf. Il n'est pas nécessaire de séparer les anticorps du jaune d'oeuf, si bien que le traitement et l'administration sont pratiques et peu onéreux. Les anticorps à base de jaune d'oeuf provenant de poules immunisées contre des antigènes spécifiques sont efficaces pour lutter contre des agents toxiques de type viral, bactérien, fongique ou protozoaire et contre les toxines, les enzymes, les médiateurs inflammatoires, les prostaglandines, les leucotriènes, les thromboxines et autres molécules messagers, les sarcomes ou les carcinomes, non seulement dans l'intestin, mais encore dans les tissus éloignés de l'intestin. Le déterminant immunogène peut renfermer uniquement une partie spécifique de l'organisme pathogène, par exemple la boucle ou l'enveloppe d'un virus ou la fimbria d'une bactérie ciliée. L'efficacité du procédé est avérée dans le traitement du SIDA chez l'homme, le choc septique à médiation par facteur de nécrose tumorale (TNF) chez la souris, et dans l'abaissement du nombre des cellules somatiques chez les bovins laitiers.
CA002267421A 1996-10-02 1997-10-02 Administration orale d'anticorps a base de jaune d'oeuf de poule pour le traitement de maladies Abandoned CA2267421A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72440896A 1996-10-02 1996-10-02
US724,408 1996-10-02
PCT/US1997/017722 WO1998014209A1 (fr) 1996-10-02 1997-10-02 Administration orale d'anticorps a base de jaune d'oeuf de poule pour le traitement de maladies

Publications (1)

Publication Number Publication Date
CA2267421A1 true CA2267421A1 (fr) 1998-04-09

Family

ID=24910322

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002267421A Abandoned CA2267421A1 (fr) 1996-10-02 1997-10-02 Administration orale d'anticorps a base de jaune d'oeuf de poule pour le traitement de maladies

Country Status (7)

Country Link
EP (1) EP0930891A4 (fr)
JP (1) JP2001501622A (fr)
KR (1) KR20000048855A (fr)
AU (1) AU729502B2 (fr)
CA (1) CA2267421A1 (fr)
NZ (1) NZ335170A (fr)
WO (1) WO1998014209A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005099753A1 (fr) * 2004-04-16 2005-10-27 The Govenors Of The University Of Alberta Anticorps de jaune d'oeuf anti-gluten pour le traitement de la maladie caeliaque
US8282928B2 (en) 2007-05-30 2012-10-09 The Governors Of The University Of Alberta Anti-gluten egg yolk antibodies for the treatment of celiac disease
CN112957464A (zh) * 2021-02-24 2021-06-15 江秀坤 一种将鸡卵黄免疫球蛋白制备成润喉保健产品的应用

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU775483B2 (en) * 1998-06-10 2004-08-05 Promega Corporation Antibodies to cytokines in the prevention and treatment of inflammatory bowel disease
US6395273B1 (en) 1998-06-10 2002-05-28 Promega Corporation Prevention and treatment of inflammatory bowel disease
US7494652B1 (en) * 1998-06-10 2009-02-24 Promega Corporation Treatment of sepsis
DE19910159A1 (de) * 1999-02-26 2000-09-14 Rosemarie Heis Spezifische lgY-Eidotterantikörper, ihre Gewinnung und ihre Verwendung
US6346247B1 (en) * 1999-10-28 2002-02-12 Promega Corporation Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies
EP1246848A1 (fr) 1999-12-27 2002-10-09 University Of Manitoba VACCINS GENETIQUES POUR LA PRODUCTION D'ANTICORPS DE JAUNE D'OEUF DE POULE DIRIGES CONTRE i ESCHERICHIA COLI /i ENTEROTOXINOGENE ET D'AUTRES PATHOGENES
KR100364198B1 (ko) * 2000-06-09 2002-12-12 영농조합법인다한 헬리코박터 파이로리에 대한 개선된 ｌｇＹ 생성의유도방법 및 이에 의해 제조된 계란
MXPA03006819A (es) * 2001-01-30 2004-10-15 Lauridsen Group Inc Metodos y composiciones para eltratamiento de transtornos de disfuncion inmune.
MXPA03006818A (es) * 2001-01-30 2004-10-15 Lauridsen Group Inc Metodos y composiciones para modular el sistema inmune de animales.
CA2339436A1 (fr) 2001-03-15 2002-09-15 Josee Harel Production d'anticorps contre les facteurs de virulence associes aux souches d'escherichia coli aeec, et leur utilisation
KR20030026502A (ko) * 2001-09-26 2003-04-03 배만종 다기능성(抗헬리코박터 파이롤리 항체, 저콜레스테롤,高디에이취에이 함유) 일반계란, 토종계란 및 청색계란생산방법
KR100392566B1 (ko) * 2001-11-13 2003-07-23 주식회사 에그 바이오택 여드름질환에 관한 프로피오니박테리움 아크네스, 스타필로코커스 에피더미디스, 대장균에 대한 항-혼합균 공유 복합특수면역단백질(IgY) 함유 계란생산 및 항-혼합균 공유 복합특수면역단백질(IgY) 제조방법
WO2003061693A1 (fr) * 2001-12-28 2003-07-31 Camas, Incorporated Adherence d'immunogenes et sa methode d'elaboration et d'utilisation
KR100489615B1 (ko) * 2002-01-30 2005-05-17 주식회사 단바이오텍 리스테리아 모노사이토제네스 감염의 예방 및 치료를 위한항체, 이를 포함하는 알 및 이들의 제조방법
KR20030079382A (ko) * 2002-04-04 2003-10-10 최태부 소화 효소-지방산 복합체를 항원으로하여 생산된 항체 및이의 이용
AU2002313212A1 (en) * 2002-06-13 2003-12-31 Kabushiki Gaisha Tokaibiken Tailor-made preparation and process for producing the same
KR20040005540A (ko) * 2002-07-10 2004-01-16 백반석 장염과 식중독의 원인물질에 대한 복합 특이 난황 항체의생산 방법
KR20040005539A (ko) * 2002-07-10 2004-01-16 백반석 이온수와 당을 이용한 계란 난황내의 수용성 특수면역단백질의 분리 및 제조
KR20040005541A (ko) * 2002-07-10 2004-01-16 선우선영 여드름 원인물질에 대한 효과적인 여러형태의 복합특이난황항체의 생산법
DK1687066T3 (da) * 2003-11-14 2012-11-26 Brigham & Womens Hospital Fremgangsmåder til immunmodulering
EP1723951A1 (fr) * 2005-04-21 2006-11-22 N.V. Nutricia Supplément nutritionnel avec des oligosaccharides pour une catégorie de patients avec HIV
JP2007082486A (ja) * 2005-09-22 2007-04-05 Daikin Ind Ltd ウイルスが感染した生物由来物の処理方法、感染ウイルスに対する処理済細胞、感染ウイルスに対する処理済組織、感染ウイルスに対する処理済臓器
JP2007084495A (ja) * 2005-09-22 2007-04-05 Daikin Ind Ltd ウイルス感染細胞処理方法
NZ575918A (en) * 2006-08-31 2012-03-30 A C N 135 493 391 Pty Ltd As Trustee For Conca Unit Trust Treatment and/or prevention of non-infectious medical conditions using antibody-containing milk or egg products
BRPI0716319A8 (pt) * 2006-10-25 2019-02-05 Aovatechnologies Inc método para reduzir a absorção de fosfato em um indivíduo animal humano ou não-humano correndo o risco de desenvolver ou que desenvolveu hiperfosfatomia e método para reduzir os efeitos colaterais da terapia de vitamina d em um ser humano
AU2011332053B2 (en) 2010-11-23 2016-06-02 Pantheryx, Inc. Compositions and methods for treatment in broad-spectrum, undifferentiated or mixed clinical applications
US20130011410A1 (en) * 2011-07-07 2013-01-10 Amicus Biotech Inc. Egg White Antibodies for Prevention and Treatment of Specific Localized Intestinal Infections and Diseases Associated with a Pathogenic Organism or Molecule
EP2746394A4 (fr) 2011-08-19 2015-07-15 Ostrich Pharma Kk Anticorps et composition le contenant
CN106749650B (zh) * 2016-12-19 2021-06-25 姚善龙 抗感冒病毒及肺链菌、葡萄球菌复合IgY抗体制备方法及其应用
KR102200721B1 (ko) * 2019-11-18 2021-01-13 (주)애드바이오텍 연어 리케차성 패혈증 예방 또는 치료용 난황항체의 제조방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4550019A (en) * 1978-03-22 1985-10-29 South Africa Inventions Development Corporation Manufacture and use of fowl egg antibodies
US4748018A (en) * 1984-02-07 1988-05-31 Stolle Research & Development Corp. Method of passive immunization of mammals using avian antibody
US5258178A (en) * 1990-07-30 1993-11-02 Abbott Laboratories Method and product for the treatment of gastric disease
US5420253A (en) * 1993-09-09 1995-05-30 Willmar Poultry Company, Inc. Method for purifying egg yolk immunoglobulins
US5585098A (en) * 1993-11-23 1996-12-17 Ovimmune, Inc. Oral administration of chicken yolk immunoglobulins to lower somatic cell count in the milk of lactating ruminants
DE19504755C2 (de) * 1995-02-02 1997-04-30 Panagiotis Tsolkas Aviäre, vitelline, gegen HIV-Antigene gerichtete Antikörper

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005099753A1 (fr) * 2004-04-16 2005-10-27 The Govenors Of The University Of Alberta Anticorps de jaune d'oeuf anti-gluten pour le traitement de la maladie caeliaque
US7854942B2 (en) 2004-04-16 2010-12-21 The Governors Of The University Of Alberta Anti-gluten egg yolk antibodies for the treatment of celiac disease
US8282928B2 (en) 2007-05-30 2012-10-09 The Governors Of The University Of Alberta Anti-gluten egg yolk antibodies for the treatment of celiac disease
CN112957464A (zh) * 2021-02-24 2021-06-15 江秀坤 一种将鸡卵黄免疫球蛋白制备成润喉保健产品的应用

Also Published As

Publication number Publication date
AU729502B2 (en) 2001-02-01
JP2001501622A (ja) 2001-02-06
WO1998014209A1 (fr) 1998-04-09
NZ335170A (en) 2001-08-31
EP0930891A4 (fr) 2001-07-04
AU4741997A (en) 1998-04-24
EP0930891A1 (fr) 1999-07-28
KR20000048855A (ko) 2000-07-25

Similar Documents

Publication Publication Date Title
AU729502B2 (en) Oral administration of chicken yolk antibodies to treat disease
JP2698779B2 (ja) トリの抗体を用いた哺乳動物の受動免疫化
KR102037885B1 (ko) 광범위한, 미확인 또는 혼합된 임상적 적용에서 치료용 조성물들 및 방법들
Kovacs-Nolan et al. Avian egg antibodies: basic and potential applications
Tsubokura et al. Oral administration of antibodies as prophylaxis and therapy in Campylobacter jejuni‐infected chickens
WO1997020577A1 (fr) Formulation therapeutique amelioree et procede correspondant
WO1994021284A1 (fr) Formulation et methode therapeutiques
Wiedemann et al. Chicken egg antibodies for prophylaxis and therapy of infectious intestinal diseases: V. in vivo studies on protective effects against Escherichia coli diarrhea in pigs
KR910005409B1 (ko) 계란으로 부터의 특이적항체함유재료의 제조방법
JPH0657663B2 (ja) 多機能特異的抗体の製造方法
US20020044942A1 (en) Transfer factor composition and process for producing same
JP2022513337A (ja) 動物の腸管感染症及び急性下痢を治療する組成物及び方法
US20040202660A1 (en) Methods and compositions for treatment of immune dysfunction disorders
MXPA03006818A (es) Metodos y composiciones para modular el sistema inmune de animales.
US20070264264A1 (en) Method and composition for conferring immunity in mammals
US20040258664A1 (en) Multifunctional complex for targeting specific phagocytosis of a target agent
Xu et al. Bovine immune colostrum against 17 strains of diarrhea bacteria and in vitro and in vivo effects of its specific IgG
Newby et al. The immune response of the pig following oral immunisation with soluble protein
Pollock et al. Effects of weaning on antibody responses in young calves
WO1996010420A1 (fr) Composition et traitement d'hyperimmunisation a l'aide de bacteries non tuees thermiquement
AU673589B2 (en) Therapeutic formulation and method
JPH05255113A (ja) 特異的抗体及びそれを配合してなるエビ類感染症防除組成物
Trisunuwati et al. Animal Health and Disease Prevention
KR100280333B1 (ko) 대장균k987p필리항원에대한난황항체의분리방법
PRITCHARD et al. WIB BEVERIDGE CE HOPLA JH GILLESPIE NORMAN D. LEVINE WR HINSHAW CA MITCHELL

Legal Events

Date Code Title Description
FZDE Dead